Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pediatric Rheumatology
Published in: Pediatric Rheumatology 1/2015

Open Access 01-12-2015 | Research article

Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis

Authors: V. Boom, J. Anton, P. Lahdenne, P. Quartier, A. Ravelli, N.M. Wulffraat, S.J. Vastert

Published in: Pediatric Rheumatology | Issue 1/2015

Login to get access

Abstract

Background

Macrophage activation syndrome (MAS) is a severe and potentially lethal complication of several inflammatory diseases but seems particularly linked to systemic juvenile idiopathic arthritis (sJIA). Standardized diagnostic and treatment guidelines for MAS in sJIA are currently lacking. The aim of this systematic literature review was to evaluate currently available literature on diagnostic criteria for MAS in sJIA and provide an overview of possible biomarkers for diagnosis, disease activity and treatment response and recent advances in treatment.

Methods

A systematic literature search was performed in MEDLINE, EMBASE and Cochrane. 495 papers were identified. Potentially relevant papers were selected by 3 authors after which full text screening was performed. All selected papers were evaluated by at least two independent experts for validity and level of evidence according to EULAR guidelines.

Results

27 papers were included: 7 on diagnosis, 9 on biomarkers and 11 on treatment. Systematic review of the literature confirmed that there are no validated diagnostic criteria for MAS in sJIA. The preliminary Ravelli criteria, with the addition of ferritin, performed well in a large retrospective case-control study. Recently, an international consortium lead by PRINTO proposed a new set of diagnostic criteria able to distinguish MAS from active sJIA and/or infection with superior performance.
Other promising diagnostic biomarkers potentially distinguish MAS complicating sJIA from primary and virus-associated hemophagocytic lymphohistiocytosis.
The highest level of evidence for treatment comes from case-series. High dose corticosteroids with or without cyclosporine A were frequently reported as first-line therapy. From the newer treatment modalities, promising responses have been reported with anakinra.

Conclusion

MAS in sJIA seems to be diagnosed best by the recently proposed PRINTO criteria, although prospective validation is needed. Novel promising biomarkers for sJIA related MAS are in need of prospective validation as well, and are not widely available yet. Currently, treatment of MAS in sJIA relies more on experience than evidence based medicine. Taking into account the severity of MAS and the scarcity of evidence, early expert consultation is recommended as soon as MAS is suspected.
Literature
1.
Stephan JL, Kone-Paut I, Galambrun C, Mouy R, Bader-Meunier B, Prieur AM. Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. Rheumatology (Oxford). 2001;40:1285–92.CrossRef
2.
Lin CI, Yu HH, Lee JH, Wang LC, Lin YT, Yang YH, et al. Clinical analysis of macrophage activation syndrome in pediatric patients with autoimmune diseases. Clin Rheumatol. 2012;31:1223–30.CrossRefPubMed
3.
Ravelli A, Magni-Manzoni S, Pistorio A, Besana C, Foti T, Ruperto N, et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr. 2005;146:598–604.CrossRefPubMed
4.
Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Annu Rev Med. 2012;63:233–46.CrossRefPubMed
5.
Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol. 2007;34:1133–8.PubMed
6.
7.
8.
Shimizu M, Yokoyama T, Yamada K, Kaneda H, Wada H, Wada T, et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology (Oxford). 2010;49:1645–53.CrossRef
9.
Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Eur J Pediatr. 2007;166:95–109.CrossRefPubMed
10.
Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124–31.CrossRefPubMed
11.
Singh S, Chandrakasan S, Ahluwalia J, Suri D, Rawat A, Ahmed N, et al. Macrophage activation syndrome in children with systemic onset juvenile idiopathic arthritis: clinical experience from northwest India. Rheumatol Int. 2012;32:881–6.CrossRefPubMed
12.
Shimizu M, Nakagishi Y, Kasai K, Yamasaki Y, Miyoshi M, Takei S, et al. Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6. Cytokine. 2012;58:287–94.CrossRefPubMed
13.
Dougados M, Betteridge N, Burmester GR, Euller-Ziegler L, Guillemin F, Hirvonen J, et al. EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis. 2004;63:1172–6.CrossRefPubMedCentralPubMed
14.
Put K, Avau A, Brisse E, Mitera T, Put S, Proost P, et al. Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-gamma. Rheumatology (Oxford). 2015;54(8):1507–17.CrossRef
15.
Assari R, Ziaee V, Mirmohammadsadeghi A, Moradinejad MH. Dynamic Changes, Cut-Off Points, Sensitivity, and Specificity of Laboratory Data to Differentiate Macrophage Activation Syndrome from Active Disease. Dis Markers. 2015;2015:424381.CrossRefPubMedCentralPubMed
16.
Minoia F, Davi S, Horne A, Demirkaya E, Bovis F, Li C, et al. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol. 2014;66:3160–9.CrossRefPubMed
17.
Bloch DA, Moses LE, Michel BA. Statistical approaches to classification, Methods for developing classification and other criteria rules. Arthritis Rheum. 1990;33:1137–44.CrossRefPubMed
18.
Davi S, Minoia F, Pistorio A, Horne A, Consolaro A, Rosina S, et al. Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2014;66:2871–80.CrossRefPubMed
19.
Minoia F, Davi S, Horne A, Bovis F, Demirkaya E, Akikusa J, et al. Dissecting the heterogeneity of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Rheumatol. 2015;42:994–1001.CrossRefPubMed
20.
Davi S, Consolaro A, Guseinova D, Pistorio A, Ruperto N, Martini A, et al. An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol. 2011;38:764–8.CrossRefPubMed
21.
Ravelli A, Minoia F, Davi S, Horne A, Bovis F, Pistorio A, Arico M, Avcin T, Behrens EM, de BF et al.: Development and initial validation of classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2015. doi: 10.​1002/​art.​39332.​ [Epub ahead of print]
22.
Kostik MM, Dubko MF, Masalova VV, Snegireva LS, Kornishina TL, Chikova IA, et al. Identification of the best cutoff points and clinical signs specific for early recognition of macrophage activation syndrome in active systemic juvenile idiopathic arthritis. Semin Arthritis Rheum. 2015;44:417–22.CrossRefPubMed
23.
Lehmberg K, Pink I, Eulenburg C, Beutel K, Maul-Pavicic A, Janka G. Differentiating macrophage activation syndrome in systemic juvenile idiopathic arthritis from other forms of hemophagocytic lymphohistiocytosis. J Pediatr. 2013;162:1245–51.CrossRefPubMed
24.
Grom AA, Villanueva J, Lee S, Goldmuntz EA, Passo MH, Filipovich A. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr. 2003;142:292–6.CrossRefPubMed
25.
Bleesing J, Prada A, Siegel DM, Villanueva J, Olson J, Ilowite NT, et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum. 2007;56:965–71.CrossRefPubMed
26.
Reddy VV, Myles A, Cheekatla SS, Singh S, Aggarwal A. Soluble CD25 in serum: a potential marker for subclinical macrophage activation syndrome in patients with active systemic onset juvenile idiopathic arthritis. Int J Rheum Dis. 2014;17:261–7.CrossRefPubMed
27.
Gorelik M, Fall N, Altaye M, Barnes MG, Thompson SD, Grom AA, et al. Follistatin-like Protein 1 and the Ferritin/Erythrocyte Sedimentation Rate Ratio Are Potential Biomarkers for Dysregulated Gene Expression and Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis. J Rheumatol. 2013;40:1191–9.CrossRefPubMed
28.
Yokota S, Itoh Y, Morio T, Sumitomo N, Daimaru K, Minota S. Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis under Treatment with Tocilizumab. J Rheumatol. 2015;42:712–22.CrossRefPubMed
29.
Shimizu M, Nakagishi Y, Inoue N, Mizuta M, Ko G, Saikawa Y, et al. Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Clin Immunol. 2015;160:277–81.CrossRefPubMed
30.
Kounami S, Yoshiyama M, Nakayama K, Okuda M, Okuda S, Aoyagi N, et al. Macrophage activation syndrome in children with systemic-onset juvenile chronic arthritis. Acta Haematol. 2005;113:124–9.CrossRefPubMed
31.
Ramanan AV, Rosenblum ND, Feldman BM, Laxer RM, Schneider R. Favorable outcome in patients with renal involvement complicating macrophage activation syndrome in systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2004;31:2068–70.PubMed
32.
Zeng HS, Xiong XY, Wei YD, Wang HW, Luo XP. Macrophage activation syndrome in 13 children with systemic-onset juvenile idiopathic arthritis. World J Pediatr. 2008;4:97–101.CrossRefPubMed
33.
Ho S, Clipstone N, Timmermann L, Northrop J, Graef I, Fiorentino D, et al. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol. 1996;80:S40–5.CrossRefPubMed
34.
Nakagishi Y, Shimizu M, Kasai K, Miyoshi M, Yachie A: Successful therapy of macrophage activation syndrome with dexamethasone palmitate. Mod Rheumatol. 2014. [Epub ahead of print]
35.
Mouy R, Stephan JL, Pillet P, Haddad E, Hubert P, Prieur AM. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr. 1996;129:750–4.CrossRefPubMed
36.
Cortis E, Insalaco A. Macrophage activation syndrome in juvenile idiopathic arthritis. Acta Paediatr Suppl. 2006;95:38–41.CrossRefPubMed
37.
Miettunen PM, Narendran A, Jayanthan A, Behrens EM, Cron RQ. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology (Oxford). 2011;50:417–9.CrossRef
38.
Prahalad S, Bove KE, Dickens D, Lovell DJ, Grom AA. Etanercept in the treatment of macrophage activation syndrome. J Rheumatol. 2001;28:2120–4.PubMed
39.
Saito K, Wagatsuma T, Toyama H, Ejima Y, Hoshi K, Shibusawa M, et al. Sepsis is characterized by the increases in percentages of circulating CD4 + CD25+ regulatory T cells and plasma levels of soluble CD25. Tohoku J Exp Med. 2008;216:61–8.CrossRefPubMed
40.
Cho E, Lee JH, Lim HJ, Oh SW, Jo SK, Cho WY, et al. Soluble CD25 is increased in patients with sepsis-induced acute kidney injury. Nephrology (Carlton). 2014;19:318–24.CrossRef
41.
Komp DM, McNamara J, Buckley P. Elevated soluble interleukin-2 receptor in childhood hemophagocytic histiocytic syndromes. Blood. 1989;73:2128–32.PubMed
42.
Moller HJ, Aerts H, Gronbaek H, Peterslund NA, Hyltoft PP, Hornung N, et al. Soluble CD163: a marker molecule for monocyte/macrophage activity in disease. Scand J Clin Lab Invest Suppl. 2002;237:29–33.CrossRefPubMed
43.
Diller R, Winde G, Kotting S, Senninger N, Dietl KH, Spiegel HU. sTNF-RII: is it useful for the early diagnosis of rejection and for prognosis after renal transplantation? Transpl Int. 2002;15:335–40.CrossRefPubMed
44.
Murr C, Widner B, Wirleitner B, Fuchs D. Neopterin as a marker for immune system activation. Curr Drug Metab. 2002;3:175–87.CrossRefPubMed
45.
46.
Chaly Y, Hostager B, Smith S, Hirsch R. Follistatin-like protein 1 and its role in inflammation and inflammatory diseases. Immunol Res. 2014;59:266–72.CrossRefPubMed
47.
Miyamae T, Marinov AD, Sowders D, Wilson DC, Devlin J, Boudreau R, et al. Follistatin-like protein-1 is a novel proinflammatory molecule. J Immunol. 2006;177:4758–62.CrossRefPubMed
48.
Wilson DC, Marinov AD, Blair HC, Bushnell DS, Thompson SD, Chaly Y, et al. Follistatin-like protein 1 is a mesenchyme-derived inflammatory protein and may represent a biomarker for systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum. 2010;62:2510–6.CrossRefPubMedCentralPubMed
49.
Sullivan KE, Delaat CA, Douglas SD, Filipovich AH. Defective natural killer cell function in patients with hemophagocytic lymphohistiocytosis and in first degree relatives. Pediatr Res. 1998;44:465–8.CrossRefPubMed
50.
Villanueva J, Lee S, Giannini EH, Graham TB, Passo MH, Filipovich A, et al. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther. 2005;7:R30–7.CrossRefPubMedCentralPubMed
51.
Zhang K, Biroschak J, Glass DN, Thompson SD, Finkel T, Passo MH, et al. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. Arthritis Rheum. 2008;58:2892–6.CrossRefPubMedCentralPubMed
52.
Vastert SJ, van Wijk R, D’Urbano LE, de Vooght KM, de Jager W, Ravelli A, et al. Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. Rheumatology (Oxford). 2010;49:441–9.CrossRef
53.
Kaufman KM, Linghu B, Szustakowski JD, Husami A, Yang F, Zhang K, et al. Whole-exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis. Arthritis Rheumatol. 2014;66:3486–95.CrossRefPubMedCentralPubMed
54.
Cooper EH, Plesner T. Beta-2-microglobulin review: its relevance in clinical oncology. Med Pediatr Oncol. 1980;8:323–34.CrossRefPubMed
55.
Hibi S, Ikushima S, Fujiwara F, Hashida T, Tsunamoto K, Todo S, et al. Serum and urine beta-2-microglobulin in hemophagocytic syndrome. Cancer. 1995;75:1700–5.CrossRefPubMed
56.
Ramanan AV, Schneider R. Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2003;30:401–3.PubMed
57.
Sandhu C, Chesney A, Piliotis E, Buckstein R, Koren S. Macrophage activation syndrome after etanercept treatment. J Rheumatol. 2007;34:241–2.PubMed
58.
Lurati A, Teruzzi B, Salmaso A, Demarco G, Pontikaki I, Gattinara M. Macrophage activation syndrome during anti-IL-1 receptor therapy (anakinra) in a patient affected by systemic onset idiopathic juvenile arthritis. Pediatr Rheumatolo Online J. 2005;3:79–85.
59.
Bruck N, Suttorp M, Kabus M, Heubner G, Gahr M, Pessler F. Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids. J Clin Rheumatol. 2011;17:23–7.CrossRefPubMed
60.
Kelly A, Ramanan AV. A case of macrophage activation syndrome successfully treated with anakinra. Nat Clin Pract Rheumatol. 2008;4:615–20.CrossRefPubMed
Metadata
Title
Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis
Authors
V. Boom
J. Anton
P. Lahdenne
P. Quartier
A. Ravelli
N.M. Wulffraat
S.J. Vastert
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Pediatric Rheumatology / Issue 1/2015
Electronic ISSN: 1546-0096
DOI
https://doi.org/10.1186/s12969-015-0055-3

Other articles of this Issue 1/2015

Pediatric Rheumatology 1/2015 Go to the issue

Research Article

Cognitive behavioral group intervention for pain and well-being in children with juvenile idiopathic arthritis: a study of feasibility and preliminary efficacy

Research article

Relationship between clinical findings and genetic mutations in patients with familial Mediterranean fever

Research

Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis

Research article

An assessment of variables affecting transition readiness in pediatric rheumatology patients

Case Report

Unusual onset of a case of chronic recurrent multifocal osteomyelitis

Research article

The experience of taking methotrexate for juvenile idiopathic arthritis: results of a cross-sectional survey with children and young people